coagulation factor XI
Última actualización 18 Aug 2020
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Ask Patient
- Versión en audio
- Agregar a fuentes preferidas en Google
El F11 gene provides instructions for making a protein called factor XI. This protein plays a role in the coagulation cascade, which is a series of chemical reactions that forms blood clots in response to injury. After an injury, clots seal off blood vessels to stop bleeding and trigger blood vessel repair.
Selecciones de videos para GenesBiblioteca de videos
Normal function
El F11 gene provides instructions for making a protein called factor XI. This protein plays a role in the coagulation cascade, which is a series of chemical reactions that forms blood clots in response to injury. After an injury, clots seal off blood vessels to stop bleeding and trigger blood vessel repair.
Factor XI is made primarily by cells in the liver. The protein circulates in the bloodstream and is normally turned off (inactive) until the coagulation cascade is turned on (activated) by an injury that damages blood vessels. When factor XI is activated, it interacts with other coagulation factors, resulting in conversion of an important coagulation protein called prothrombin to its active form, thrombin. Thrombin then converts a protein called fibrinogen into fibrin, which is the material that forms blood clots.
Conditions referring to this gene or chromosome
Otros nombres
coagulation factor XI preproprotein
FXI
plasma thromboplastin antecedent
PTA
Related patient information and medicines

Patient information leaflet
Pruebas de coagulación sanguínea
Pruebas de coagulación sanguínea are used to diagnose and assess bleeding problems and to monitor people who take warfarina u otro anticoagulante medicines. You may be advised to have blood clotting tests: If you h... These chemicals then react with other chemicals and proteins in the plasma, called clotting factors. There are 13 known clotting factors which.

Patient information leaflet
Anticoagulantes
DOACs are much m... In 2021, the UK's National Institute for Health and Care Excellence (NICE) recommended that DOACs should be the preferred option for AF, instead of warfarin. Speak to your doctor if you'd like to consider changing your anticoagulant. These activated platelets and the damaged tissue release chemicals which react with other.

Patient information leaflet
Pre-eclampsia
The National Institute for Health and Care Excellence (NICE) recommends that women at increased risk of developing pre-eclampsia should take low-dose aspirin. NICE recommends 75-150 mg asp... The risk of complications is reduced if pre-eclampsia is diagnosed early and treated. A rare pero serious complication is disseminated intravascular.

Patient information leaflet
Trombofilia
El clotting cascade makes the blood solidify into a clot, which sticks to the injured part of the blood vessel. Small particles in the blood, called platelets, also help to form the clot. There are also natural chemicals in the blood which act against the clotting system, to stop the blood clotting too much. Thrombophilia occurs if the normal.

Patient information leaflet
esófago de Barrett
Barrett'. It typically affects people between the ages of 50 and 70 years. The coil then emits heat ene... Nearby normal cells then multiply and replace the destroyed abnormal cells. Argon plasma coagulation This treatment uses a jet of argon gas, together with an electric current, to burn away dysplastic cells. Endoscopic mucosal resection (EMR).

Patient information leaflet
Hemorroides
Banding treatment (rubber band ligation) Banding is the most commonly used hemorroides treatment, especially for grade 2 and 3 piles. Coagulación/Foto-coagulación infrarroja This method of piles treatment uses infrared light to burn and cut off the circulation to the haemorrhoid, which causes it to shrink in size. It may be as effective as banding.
Lecturas adicionales y referencias
- coagulation factor XI; MedlinePlus, National Library of Medicine.
- Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013 Sep;39(6):621-31. doi: 10.1055/s-0033-1353420. Epub 2013 Aug 8.
- Duga S, Salomon O. Factor XI Deficiency. Semin Thromb Hemost. 2009 Jun;35(4):416-25. doi: 10.1055/s-0029-1225764. Epub 2009 Jul 13.
- Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood. 2010 Apr 1;115(13):2569-77. doi: 10.1182/blood-2009-09-199182. Epub 2010 Jan 28.
- Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia. 2008 Nov;14(6):1183-9. doi: 10.1111/j.1365-2516.2008.01667.x. Epub 2008 Feb 27.
- He R, Chen D, He S. Factor XI: hemostasis, thrombosis, and antithrombosis. Thromb Res. 2012 May;129(5):541-50. doi: 10.1016/j.thromres.2011.11.051. Epub 2011 Dec 22.
- Peretz H, Salomon O, Mor-Cohen R, Usher S, Zucker M, Zivelin A, Seligsohn U. Type I mutation in the F11 gene is a third ancestral mutation which causes factor XI deficiency in Ashkenazi Jews. J Thromb Haemost. 2013 Apr;11(4):724-30. doi: 10.1111/jth.12137.
- Puy C, Rigg RA, McCarty OJ. The hemostatic role of factor XI. Thromb Res. 2016 May;141 Suppl 2(Suppl 2):S8-S11. doi: 10.1016/S0049-3848(16)30354-1.
Comparte tus pensamientos o experiencias con otros en nuestro comunidades de pacientes.
Suscríbete al boletín de Patient
Tu dosis semanal de consejos de salud claros y confiables, escritos para ayudarte a sentirte informado, seguro y en control.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.

